life scienc diagnost tool
choppi perform ytd also reassur
trend reduc pt buy
lower pt maintain buy wat top
line perform miss guidanc report earlier week
unquestion disappoint despit pocket weak cite
certain end market european pharma modest improv
india think ultim boil execut wat mix
perform ytd also stick market environ wat
peer group post record organ growth rate exhibit
observ first time sever year broad-bas strength
across geograph region custom segment still
optimist pessimist wat outlook ahead
believ full year guidanc suffici reduc well within reach
even beatabl recur revenu growth remain bright spot
think speak durabl wat busi model
competit displac may perceiv concern also
havent seen consist under-perform one product categori
end market segment quarter quarter despit lacklust top line
perform earn perform solid ytd due oper
leverag cash flow deploy capabl acceler
invest last sever year begin bear fruit
potenti top line acceler next month
acquiti arc uplc begin gain momentum year
bio-tof slate launch plan
aggress capit deploy revis pt repres
modest premium price-to-earnings basi compar peer group large-cap lst
compani think justifi base wat industry-lead
margin exhibit cash flow profil exhibit
model updat revis revenu ep est
y/i vs prior y/i vs
prior revis revenu ep est
y/i y/i vs unchang
valuat pt base price-to-earnings
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
exhibit organ revenu growth peer base
guidanc octob fye
base guidanc peer group includ
exhibit ebitda margin vs peer base consensu
exhibit yield vs peer group base ytd
exhibit varianc million except per share data
exhibit segment detail growth constant currenc
flat strength stand-alone
core lc lc-m sold
pharma custom
driven ms
flat driven ms
full year
full
full
actualguidancestreet estimate btig chang cc gross incom oper margin rate incom chang incl
exhibit end market color geographi growth constant currenc
 growth broad-
strength ta
pick spend
mid-siz larg
pharma custom
cautiou
earlier year
across region
pharma medic
strength small
continu strong
demand biopharma
larg
grow instal base
china grew
strong comparison
across key end
full year
india rebound
disrupt due
new gst system
grew hsd
steadi growth japan
growth america
soft biomed
research well slower
expect pharma
instrument
solid growth pharma
weak biomed
growth canada
industri
drag region
rico strong
industri
strong
strength larg molecul
 sale flat
increas strength
pharma off-set soft
clinic applic
instrument product
strong growth canada
latin america
uncertainti head
end
weak clinic
applic
china sale
weak india
japan lsd in-
line compani
china driven
china grew mid-
pharma food
japan lsd growth
teen driven strong
growth pharma food
fine chemic market
off-set soft ta
modest growth india
full year
exhibit end market color custom type growth constant currenc
strong demand
doubl digit growth
doubl digit growth
china solid rebound
doubl digit growth
china msd
declin notabl
comparison prior
slight declin
slower expect
budget releas larg
softer demand food
environment
strength chemic
nice improv
continu trend
modest declin
declin sale clinic
strength chemic
analysi food
strong growth asia
across major
america
partial off-set softer
demand europ
weak biomed
research off-set
strength
pharma discoveri
mass spec sale
chemic food
custom due part
territori realign
ta continu strong
year grew
industri china
strong growth china
driven food research
perform across
strong spend
weak
weak biomed
focus biomed
omic research
custom
research
off-set improv
research
continu stabl demand
pharma industri end
demand pharma
less tailwind
consist growth recur
y/i growth industri
consist growth
consist prior year
growth rate sale growth
reduct y/i due increas
flexibl deploy wat
cash balanc result tax
posit impact lower
tax rate approxim
unfavour impact due
intang base broaden
provis lower tax
benefit stock compens
result tax rate
reduct
continu share
repurchas program
approxim compar
benefit tax rate
reduct tax reform
neutral impact fx
share repurchas
fiscal year end dec million except per share profit develop intang incom expens oper incom incom incom analysiscost margin gener administr develop margin tax margin growthnet margin bpsoper incom margin bpsnet incom compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
